Apyx Medical Corp.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US03837C1062
USD
4.03
-0.04 (-0.98%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Apyx Medical Corp. stock-summary
stock-summary
Apyx Medical Corp.
Pharmaceuticals & Biotechnology
Apyx Medical Corporation, formerly Bovie Medical Corporation, is an energy-based medical device company. The Company is engaged in the design, development and manufacturing of electrosurgical equipment by producing equipment for medical device manufacturers through original equipment manufacturing (OEM) agreements, as well as start-up companies. It operates through two segments: OEM and J-Plasma. It is engaged in developing and marketing a range of electrosurgical products and technologies, as well as related medical products used in doctor's offices, surgery centers and hospitals around the world. It also develops J-Plasma, a helium-based plasma surgical product. The J-Plasma system consists of an electrosurgical generator unit, a handpiece and a supply of helium gas. Its products are marketed through brands, including Aaron, DERM, IDS and ICON, and on a private label basis to distributors around the world. It offers products in electrosurgery, cauteries and other products categories.
Company Coordinates stock-summary
Company Details
5115 Ulmerton Rd , CLEARWATER FL : 33760-4004
stock-summary
Tel: 1 727 3842323
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 11 Schemes (12.72%)

Foreign Institutions

Held by 17 Foreign Institutions (2.86%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Andrew Makrides
Independent Chairman of the Board
Mr. Charles Goodwin
Chief Executive Officer, Director
Mr. John Andres
Independent Vice Chairman of the Board
Mr. Lawrence Waldman
Lead Independent Director
Ms. Minnie Baylor-Henry
Independent Director
Mr. Michael Geraghty
Independent Director
Mr. Craig Swandal
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
11 Million
(Quarterly Results - Jun 2025)
Net Profit:
-4 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 78 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.75

stock-summary
Return on Equity

-238.43%

stock-summary
Price to Book

10.74